Cognitive impairment in first-episode schizophrenia (FES) is the symptom that does the most work blocking employment, relationships, and independent living — and the symptom current antipsychotics barely move. A 2026 RCT by Hu et al. in Psychological Medicine tested whether 20 sessions of low-frequency rTMS targeting the right orbitofrontal cortex (OFC) could improve cognition where …
Anorexia nervosa (AN), a severe mental disorder characterized by an intense fear of gaining weight and a distorted body image, remains a formidable challenge in psychiatric treatment. Recent research has shone a light on the potential of olanzapine, an atypical antipsychotic, in offering new hope through both systemic and innovative intranasal administration methods in animal …
It is estimated that 40% of U.S. adults are obese – and this figure is projected to continue growing. One potential reason for weight gain and a possible catalyst for obesity is use of pharmaceutical drugs (i.e. medications). Medication-induced weight gain poses a significant challenge in healthcare, affecting both patient well-being and treatment adherence. Key …
Zyprexa (Olanzapine) is an atypical antipsychotic medication that is approved by the FDA for the treatment of schizophrenia and bipolar disorder. In relatively rare cases, it is used as an augmentation strategy for the treatment of depression. The drug is manufactured by the company Eli Lilly, and has generated billions of dollars in revenue. Despite …
Zyprexa (Olanzapine) is an atypical antipsychotic drug that is commonly utilized for the treatment of schizophrenia and bipolar disorder. It works more on serotonin receptors than dopamine receptors, but targets both. Although this is a drug that can work well for treating severe mental illnesses, more than 50% of people quit taking it during clinical …